Production (Stage)
E
Moleculin Biotech, Inc. MBRX
$0.67 -$0.0201-2.91% NASDAQ
Recommendation
Prev Close
$0.67
Volume
786,611
Avg Vol (90D)
4,164,606
Market Cap
$9.47M
Dividend & Yield
--
52-Week Range
$0.3975 - $4.90
P/E (TTM)
--
EPS (TTM)
-$5.61
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Moleculin Biotech Hosts Key Opinion Leaders Event
6/5/2025 - TipRanks Financial Blog
Moleculin Biotech (MBRX) Presents Final Data from Annamycin Clinical Trial MBRX Stock News
6/5/2025 - GuruFocus
Moleculin Biotech releases KOL webcast to discuss Phase 1B/2 annamycin data
6/5/2025 - The Fly
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)
6/5/2025 - Globe Newswire
Moleculin Biotech (MBRX) Reports Promising Phase 1B/2 Trial Results for Annamycin MBRX Stock News
6/4/2025 - GuruFocus
Moleculin Biotech reports efficacy results from Phase 1B/2 trial of annamycin
6/4/2025 - The Fly
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
6/4/2025 - Globe Newswire
Roth Capital Partners Manages New Developments for Moleculin Biotech (MBRX) MBRX Stock News
6/2/2025 - GuruFocus
Moleculin Biotech files to sell 10.99M shares of common stock, warrants
6/2/2025 - SeekingAlpha.com: All News
Moleculin Biotech files to sell 10.99M shares of common stock, warrants
6/2/2025 - TipRanks Financial Blog
Moleculin Biotech files to sell 10.99M shares of common stock, warrants
6/2/2025 - The Fly
Moleculin Biotech Faces Nasdaq Non-Compliance Notice
5/23/2025 - TipRanks Financial Blog
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ...
5/15/2025 - GuruFocus
Q1 2025 Moleculin Biotech Inc Earnings Call Transcript
5/15/2025 - GuruFocus
Moleculin Biotech Reports Q1 2025 Financial Results
5/15/2025 - TipRanks Financial Blog
Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
5/14/2025 - SeekingAlpha
Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
5/14/2025 - Seeking Alpha: Transcripts
Moleculin Biotech GAAP EPS of -$0.69
5/14/2025 - SeekingAlpha.com: All News
Moleculin Biotech reports Q1 EPS (69c) vs ($2.02) last year
5/14/2025 - The Fly
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
5/14/2025 - Globe Newswire
Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On 'Low And Slow' Setup
5/13/2025 - Stocktwits News Feed
Moleculin Biotech (MBRX) Gains EMA Approval for Pivotal Phase 2B/3 AML Trial MBRX Stock News
5/12/2025 - GuruFocus
Moleculin Biotech receives EMA approval to expand Phase 3 MIRACLE trial
5/12/2025 - TipRanks Financial Blog
Moleculin Biotech receives EMA approval to expand Phase 3 MIRACLE trial
5/12/2025 - The Fly
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
5/12/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$25.78M
EBIT (TTM)
-$25.91M
Net Income (TTM)
-$23.23M
Balance Sheet
Total Assets (Q)
$21.01M
Total Debt (Q)
$450.00K
Total Liabilities (Q)
$20.97M
Book Value Per Share (Q)
$0.003
Cash Flow
Cash from Operations (TTM)
-$21.71M
Cash from Investing (TTM)
-$13.00K
Cash from Financing (TTM)
$12.63M
Net Change in Cash (TTM)
-$9.11M
Filings
Filing Date
Tuesday, May 13, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
1.72
7-Day Total Return
-26.20%
30-Day Total Return
-36.79%
60-Day Total Return
-42.24%
90-Day Total Return
-56.77%
Year to Date Total Return
-62.15%
1-Year Total Return
-84.49%
2-Year Total Return
-93.18%
3-Year Total Return
-96.96%
5-Year Total Return
-99.32%
52-week Low
Feb 12, 2025 - $0.3975
52-week High
Jun 14, 2024 - $4.90
Valuation
Market Cap
$9.47M - Nano Cap
Enterprise Value
$2.20M
Price/Sales (TTM)
--
Price/Book (Q)
223.33
Dividends and Shares
Shares Outstanding
9.34M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
moleculin.com
Phone Number
(713) 300-5160
Address
5300 Memorial Drive
Houston, TX 77007
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin... more
NASDAQ 06/06/2025 4:00PM Eastern Quotes delayed